The agency says pairing drug sponsors with research institutions could cut development timelines by 6 to 12 months ...
The US Food and Drug Administration (FDA) is seeking comments on a pilot program where qualified external institutions will ...
The FDA’s efforts are meant to reduce phase 1 timelines by six to 12 months, Diamantas said. They include what he called an ...
Why does it take a new drug 10 years, on average, to come to market? Part of the reason lies in the dead time in the process. Historically, trials have required tedious tabulations and repeated ...
Announcing a new article publication for BIO Integration journal. Clinical trials bridge basic research and clinical application, serving as essential steps in drug development. This review examines ...
FDA proof-of-concept trials with AstraZeneca and Amgen validate continuous data transmission and signal detection, setting ...
WHITE OAK, MD – The US Food and Drug Administration (FDA) has announced plans for a future pilot program intended to facilitate the real-time review of clinical trials by regulators, as well as the ...
Paradigm Health, the sole technology provider operationalizing the U.S. Food and Drug Administration's (FDA) Real-Time Clinical Trials (RTCT) proof-of-concept studies, has formally submitted its ...
Clinical Trials Arena on MSN
Ascletis receives FDA clearance for Phase I trial of obesity treatment
The study aims to evaluate ASC35’s safety, tolerability, pharmacokinetics and pharmacodynamics.
GlobalData on MSN
NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial
PrimeC is now FDA-cleared to enter Phase III development in ALS, as competition in the indication intensifies with several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results